Navigation Links
Mylan Announces Strategic Collaboration with Biocon to Enter the Global Generic Biologics Market
Date:6/29/2009

PITTSBURGH, June 29 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today announced that it has executed a definitive agreement with Biocon Limited, a publicly traded company on the Indian stock exchanges, for an exclusive collaboration on the development, manufacturing, supply and commercialization of multiple, high value generic biologic compounds for the global marketplace. Through this partnership, Mylan and Biocon bring together highly complementary capabilities that will significantly advance their efforts to secure a leading position in the emerging generic biologics industry.

Mylan's Chairman and CEO Robert J. Coury commented: "Biocon is a first-class, highly respected organization, and I am extremely excited to be able to announce what I consider to be one of the more comprehensive and high quality biologics initiatives reported within the industry to date. After working with our Senior Vice President and Head of Global Biologics Dr. Patrick Vink and conducting extensive due diligence, I can tell you that Biocon is truly an ideal partner for Mylan."

Coury continued: "This unique collaboration combines Biocon's scientific expertise; excellent product development track record; appreciation of complex regulatory requirements; and state-of-the-art, cost-efficient and scalable biologics manufacturing with Mylan's one-of-a-kind global commercial footprint and our regulatory expertise around the world. Biocon also has a unique corporate culture that is very similar to Mylan's. All of these attributes will provide a critical synergy and create a strong and effective long-term partnership. Generic biologics, especially monoclonal antibodies, are expected to become the next great bolus of growth in the generic pharmaceutical industry, and through this alliance, Mylan and Biocon have covered all four corners of what any organizati
'/>"/>

SOURCE Mylan Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Mylan Again Calls for an End to Authorized Generics During 180-Day Exclusivity Period
2. Mylan Receives Tentative FDA Approval for Generic Version of Singulair(R)
3. Mylans Matrix Selected by the Clinton HIV/AIDS Initiative and UNITAID as the Primary Supplier of Five Second-Line and Seven Pediatric HIV/AIDS Treatments
4. Mylans Matrix Receives First Tentative FDA Approval Under PEPFAR for Generic Truvada(R)
5. Mylan Confirms Four First-to-File Challenges
6. Shire Files Lawsuit Against Mylan for Infringement of FOSRENOL(R) (Lanthanum Carbonate) Patent
7. Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008
8. Shire Receives FOSRENOL Paragraph IV Notice Letters from Barr Laboratories and Mylan
9. Cephalon and Eurand File Patent Infringement Lawsuit Against Mylan Pharmaceuticals and Barr Pharmaceuticals
10. Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008
11. Mylan Confirms First-to-File Patent Challenge Relating to Lescol(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... 21, 2014   ... Commercial Officer zu KLOX    ... Chief Financial Officer bestellt    KLOX ... seines jüngst zugelassenen Behandlungssystems zur Wundheilung zu beginnen    ... "Unternehmen") ist sehr erfreut, die folgenden personellen Veränderungen anzukündigen: ...
(Date:11/21/2014)... November 20, 2014 Offering a complete ... Sartorius Entris Balance promotion . The Sartorius Entris Balance ... durable, high accuracy, and easy-to-maintain balance entry level balance. ... It was designed to help customer’s bridge the gap ... balance that is very durable. Sartorius is the second ...
(Date:11/21/2014)... New York, NY (PRWEB) November 20, 2014 ... ) is now available as an open access journal ... cells with infrared fluorescent proteins to preserve photoresponsiveness in ... Two-color fluorescent in situ hybridization using chromogenic ... microfluidics chips for DNA, RNA, and protein electrophoresis , ...
(Date:11/21/2014)... Texas (PRWEB) November 21, 2014 ... is a professional and in-depth research report on ... including its definition, classification, application, and industry chain ... covers the international market analysis, including China’s domestic ... macroeconomic environment & economic situation analysis. The report ...
Breaking Biology Technology:KLOX Technologies meldet Neubesetzung von Führungspositionen 2KLOX Technologies meldet Neubesetzung von Führungspositionen 3KLOX Technologies meldet Neubesetzung von Führungspositionen 4KLOX Technologies meldet Neubesetzung von Führungspositionen 5Pipette.com Announces an Extension on the Sartorius Entris Balance Promotion to the End of 2014 2BioTechniques: The International Journal of Life Science Methods Announces the Publication of the November 2014 Issue—Available in Print and Online 2BioTechniques: The International Journal of Life Science Methods Announces the Publication of the November 2014 Issue—Available in Print and Online 3International Transformer Industry - Analysis on Applications, Development & Forecasts Now Available at ReportsnReports.com 2International Transformer Industry - Analysis on Applications, Development & Forecasts Now Available at ReportsnReports.com 3
... Nov. 27 Nastech,Pharmaceutical Company Inc. (Nasdaq: NSTK ... Capital Markets Focus on Healthcare Conference on,Wednesday, December 5, ... Hotel in New York City., To access the ... to,Nastech,s website at http://www.nastech.com approximately 15 minutes ...
... FDA 510(k) (Pre-Market Notification), Pathway for AppyScore(TM), the First Blood-based Screening ... ... Colo., Nov. 27 AspenBio Pharma,Inc. (Nasdaq: APPY ) an ... for animals and humans, has,received an official response from the Food ...
... - Oncolytics Biotech Inc. (TSX:,ONC, NASDAQ: ONCY) ("Oncolytics") ... 7,300,650 entitled "Reovirus for the Treatment of Neoplasia.",The ... treat cancers that,have inactivated PKR, whether the PKR ... factors. PKR is a host cellular protein responsible ...
Cached Biology Technology:AspenBio Pharma Pursues FDA 510(k) Application Pathway for Appendicitis Blood Test 2AspenBio Pharma Pursues FDA 510(k) Application Pathway for Appendicitis Blood Test 3AspenBio Pharma Pursues FDA 510(k) Application Pathway for Appendicitis Blood Test 4Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent 2
(Date:11/21/2014)... November 18, 2014 According to ... by Systems (Video, RFID, Access Control, Intrusion Detection, Parking ... Banks, Government), Component Service Geography - Global Forecasts to ... is projected to be around $25 Billion in 2014 ... growing at a CAGR of 8.69%. Browse ...
(Date:11/21/2014)... Nov. 19, 2014  Earlier this year Donald ... College, and one of the most prolific inventors in ... are transmitted from Smartphones to third party agencies. Spector ... has one of the earliest known patents in this ... in the military, child care, elder care and hospital ...
(Date:11/21/2014)... VIEW, Calif. , Nov. 20, 2014 ... higher driver efficiency are piloting the North American and ... number of accidents growing, gesture recognition systems that are ... make a mark in the industry. ... the Automotive Gesture Recognition Market in Europe ...
Breaking Biology News(10 mins):Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 2Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 4
... CLEVELAND/ORLANDO University Hospitals Case Medical Center researchers ... a second chancejust not as they originally thought. ... harnessed from bone marrow that were believed to have ... if injected into the heart within two weeks of ...
... step closer to understanding what drives tumor metastasis, as ... can slow their own growth. In a recent ... the American Association for Cancer Research, Ral A. Ruggiero, ... medicine at the National Academy of Medicine in Buenos ...
... Findings from preclinical studies in a skin ... alone, or first-generation BRAF inhibitors used in combination ... have the potential to prevent drug-induced skin lesions ... The studies, presented at the AACR-NCI-EORTC International ...
Cached Biology News:Post heart attack recovery may not be aided by stem cell injections, but trial demonstrates promise 2New approaches may prevent certain side effects in BRAF mutation-positive melanoma 2
Kit Components: Anti-Acetylated Histone H3 Salmon Sperm DNA/Protein A Agarose All necessary buffers. ...
Liquid. 50 μg/ml in PBS, pH 7.4. PROTECT FROM LIGHT. A convenient form of propidium iodide useful for flow cytometry studies. RTECS SF7949600, CAS 25535-16-4, M.W. 668.4. ...
Lyophilized solid. Suitable for evaluating functional activity of human complement components and for other research requiring a high level of hemolytic activity. ...
... ChipWriter Pro systems are high-precision microarrayers ... other biological samples. VersArray ChipWriter Pro ... spot density, and reproducibility to deliver ... of substrates. Their modular component design ...
Biology Products: